- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection
A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.
EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC
EP: 2.Strategies to Increase Biomarker Testing Rates
EP: 3.Limitations on Optimal Biomarker Testing Rates
EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes
EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC
EP: 6.NCCN Recommendations by PD-L1 Expression Level
EP: 7.Limitations of NCCN PD-L1 Expression Recommendations
EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC
EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC
EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response
EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection
EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches
EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations
Video content above is prompted by the following questions:
- Outside of biomarkers, what clinical factors also lead to immune checkpoint inhibitor therapy underperformance?
- How can patient selection be optimized among those less likely to respond to immune checkpoint inhibitor therapy?
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Read More
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
July 1st 2025Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Read More
FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC
June 23rd 2025The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.
Read More
Taletrectinib Approved for ROS1-Positive NSCLC
June 11th 2025This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for the same patient population, as well as additional non–small cell lung cancer (NSCLC) indications.
Read More
